{
    "id": "dbpedia_8014_1",
    "rank": 59,
    "data": {
        "url": "https://www.ucl.ac.uk/centre-for-neuromuscular-diseases/partners-and-networks/industry-partners",
        "read_more_link": "",
        "language": "en",
        "title": "Industry Partners",
        "top_image": "https://cdn.ucl.ac.uk/indigo/images/twitter-card-ucl-logo.png",
        "meta_img": "https://cdn.ucl.ac.uk/indigo/images/twitter-card-ucl-logo.png",
        "images": [
            "https://cdn.ucl.ac.uk/indigo/images/close.png",
            "https://cdn.ucl.ac.uk/indigo/images/ucl-logo.svg",
            "https://cdn.ucl.ac.uk/img/blank.gif",
            "https://www.ucl.ac.uk/centre-for-neuromuscular-diseases/sites/centre_for_neuromuscular_diseases/files/styles/medium_image/public/acceleron.png?itok=heNkO1yz",
            "https://www.ucl.ac.uk/centre-for-neuromuscular-diseases/sites/centre_for_neuromuscular_diseases/files/styles/medium_image/public/biomarin.png?itok=Ns8LCwZP",
            "https://www.ucl.ac.uk/centre-for-neuromuscular-diseases/sites/centre_for_neuromuscular_diseases/files/styles/medium_image/public/genethon.jpg?itok=NIWMXU1t",
            "https://www.ucl.ac.uk/centre-for-neuromuscular-diseases/sites/centre_for_neuromuscular_diseases/files/styles/medium_image/public/gsk.jpg?itok=nQ7N3_LJ",
            "https://www.ucl.ac.uk/centre-for-neuromuscular-diseases/sites/centre_for_neuromuscular_diseases/files/styles/medium_image/public/novartis.jpg?itok=ODbv6zTP",
            "https://www.ucl.ac.uk/centre-for-neuromuscular-diseases/sites/centre_for_neuromuscular_diseases/files/styles/medium_image/public/orphazyme.png?itok=I_ESHOL5",
            "https://www.ucl.ac.uk/centre-for-neuromuscular-diseases/sites/centre_for_neuromuscular_diseases/files/styles/medium_image/public/pfizer.jpg?itok=vd-vkNGn",
            "https://www.ucl.ac.uk/centre-for-neuromuscular-diseases/sites/centre_for_neuromuscular_diseases/files/styles/medium_image/public/ptc-therapeutics.jpg?itok=w_DuEu0f",
            "https://www.ucl.ac.uk/centre-for-neuromuscular-diseases/sites/centre_for_neuromuscular_diseases/files/styles/medium_image/public/santhera.jpg?itok=4_DFIzaL",
            "https://www.ucl.ac.uk/centre-for-neuromuscular-diseases/sites/centre_for_neuromuscular_diseases/files/styles/medium_image/public/summit.jpg?itok=eFgg4bYb",
            "https://cdn.ucl.ac.uk/img/twitter-x.png",
            "https://cdn.ucl.ac.uk/img/35x35xfacebook.png.pagespeed.ic.-VUStBF1gm.png",
            "https://cdn.ucl.ac.uk/img/35x35xyoutube-icon-square.png.pagespeed.ic.GcRcZjQawu.png",
            "https://cdn.ucl.ac.uk/img/35x35xsoundcloud.png.pagespeed.ic.BdtBaqtDmd.jpg",
            "https://cdn.ucl.ac.uk/img/35x35xflickr.png.pagespeed.ic.KdAnMQjbrP.png",
            "https://cdn.ucl.ac.uk/img/35x35xinstagram-badge.png.pagespeed.ic.OPAzj9OMyV.png",
            "https://cdn.ucl.ac.uk/img/tiktok.png"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [],
        "publish_date": "2019-09-26T15:56:32+01:00",
        "summary": "",
        "meta_description": "",
        "meta_lang": "en",
        "meta_favicon": "https://www.ucl.ac.uk/centre-for-neuromuscular-diseases/sites/all/themes/indigo/favicon.ico",
        "meta_site_name": "Queen Square Centre for Neuromuscular Diseases",
        "canonical_link": "https://www.ucl.ac.uk/centre-for-neuromuscular-diseases/partners-and-networks/industry-partners",
        "text": "Acceleron Pharma (USA)\n\nAcceleron is a privately held biopharmaceutical company committed to discover, develop, manufacture and commercialise novel biotherapeutics that treat musculoskeletal, metabolic and cancer-related diseases.\n\nBioMarin Pharmaceutical Inc (USA)\n\nFounded in 1997, BioMarin has developed and commercialized four products in this time. With over 700 employees and a head office in California, clinical research is conducted on an international scale with the main area of focus being rare 'orphan' genetic diseases.\n\nGénéthon (France)\n\nFirst a pioneer of human genome research, Genethon now explores the new therapeutic hypotheses stemming from the extraordinary progresses of contemporary biology.\n\nGlaxoSmithKline (UK)\n\nGlaxoSmithKline produce medicines that treat major disease areas such as asthma, virus control, infections, mental health, diabetes and digestive conditions. In addition, they are a leader in the important area of vaccines and are developing new treatments for cancer.\n\nNovartis (Switzerland)\n\nNovartis has five business segments and is supported by its global research organization, the Novartis Institutes for BioMedical Research (NIBR). These segments are strategically aligned to bring innovative, high-quality and affordable medicines and therapies to patients around the world.\n\nOrphazyme (Denmark)\n\nOrphazyme ApS (Copenhagen, Denmark) develops new therapies for the treatment of rare and genetic diseases.\n\nPfizer (USA)\n\nSince Pfizer was founded by cousins Charles Pfizer and Charles Erhart in 1849, the pharmaceutical company has remained dedicated to discovering and developing new, and better, ways to prevent and treat disease and improve health and well being for people around the world.\n\nPTC Therapeutics (USA)\n\nPTC Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialisation of orally administered, proprietary small-molecule drugs that target post-transcriptional control processes.\n\nSanthera Pharmaceuticals (USA)\n\nSanthera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focusing on the development and marketing of innovative pharmaceutical products for the treatment of orphan neuromuscular diseases."
    }
}